A
A-Bio Materials
Innovative exosome-based cosmetic solutions leveraging advanced stem cell technology for enhanced skin health
About A-Bio Materials
ABio operates in the biotechnology sector, specializing in the development and commercialization of exosome-based cosmetic products. The company serves clients in the beauty and skincare industry, including major cosmetic brands and research institutions. ABio's core business model revolves around the isolation and purification of exosomes from various plant and human stem cell sources, which are then incorporated into cosmetic formulations. These exosomes are tiny vesicles that facilitate cell-to-cell communication and have shown potential in promoting skin regeneration and health. ABio generates revenue through the sale of its proprietary exosome-based ingredients and through collaborative research and development partnerships. The company holds several patents for its innovative purification processes and has established technical partnerships to enhance its product offerings. ABio's market is primarily focused on high-end skincare products that demand cutting-edge biotechnology solutions. The company also benefits from government-sponsored projects and collaborations with leading cosmetic companies, which further bolster its market position.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- South Korea
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Oct 2025 | $13M | $52M | Undisclosed | ↗ |
| ANGELEquity / VC | Jul 2022 | $0 | — | Undisclosed | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 exomasNeural stem cell exosomes for neurodegenerative diseases |
Rosario, Argentina | Operational | 5 | $250K | $1M |
 Pre-CureAdvanced tumor-on-a-chip technology enables precise cancer treatment selection through simulated physiological tumor behavior |
Israel | Operational | |||
 BioScriptA hospital and pharmacy system that uses patient fingerprints for secure prescription and medication management |
Nakhchivan, Azerbaijan | Operational | |||
 Sintez Company SIADevelopers of food and health products from natural ingredients |
— | Operational | |||
 Ysotope TheranosticsTargeted radiopharmaceuticals for precision oncology |
Madrid, Spain | Operational | |||
 Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases |
Aarhus, Denmark | Operational | |||
 Onena MedicinesRevolutionary AI-optimized medicines delivering hope where it’s needed most |
Allschwil, Switzerland | Operational | |||
 MedHydrogelDeveloping therapeutic contact lenses with super-absorptive properties |
Riga, Latvia | Closed |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about A-Bio Materials on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See A-Bio Materials’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.